Candriam SCA’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-380,000
| Closed | -$395K | – | 866 |
|
|
2019
Q1 | $395K | Hold |
380,000
| – | – | 0.01% | 742 |
|
|
2018
Q4 | $284K | Hold |
380,000
| – | – | ﹤0.01% | 750 |
|
|
2018
Q3 | $806K | Hold |
380,000
| – | – | 0.01% | 661 |
|
|
2018
Q2 | $878K | Buy |
380,000
+60,000
| +19% | +$175K | 0.01% | 636 |
|
|
2018
Q1 | $1.02M | Hold |
320,000
| – | – | 0.02% | 593 |
|
|
2017
Q4 | $1.31M | Sell |
320,000
-50,000
| -14% | -$218K | 0.02% | 532 |
|
|
2017
Q3 | $1.67M | Buy |
370,000
+156,000
| +73% | +$632K | 0.03% | 488 |
|
|
2017
Q2 | $713K | Hold |
214,000
| – | – | 0.01% | 625 |
|
|
2017
Q1 | $1.97M | Buy |
214,000
+7,000
| +3% | +$61.5K | 0.04% | 451 |
|
|
2016
Q4 | $1.6M | Buy |
207,000
+40,000
| +24% | +$368K | 0.04% | 412 |
|
|
2016
Q3 | $1.91M | Hold |
167,000
| – | – | 0.05% | 365 |
|
|
2016
Q2 | $2.06M | Buy |
167,000
+62,000
| +59% | +$752K | 0.05% | 304 |
|
|
2016
Q1 | $1.06M | Sell |
105,000
-20,700
| -16% | -$243K | 0.03% | 420 |
|
|
2015
Q4 | $2.83M | Buy |
125,700
+35,000
| +39% | +$717K | 0.08% | 257 |
|
|
2015
Q3 | $1.5M | Buy |
90,700
+10,700
| +13% | +$215K | 0.04% | 381 |
|
|
2015
Q2 | $1.8M | Sell |
80,000
-40,000
| -33% | -$986K | 0.04% | 378 |
|
|
2015
Q1 | $3.09M | Buy |
120,000
+30,000
| +33% | +$761K | 0.06% | 333 |
|
|
2014
Q4 | $1.96M | Buy |
+90,000
| New | +$1.84M | 0.04% | 355 |
|
Candriam SCA's OMED Position: Q2 2019 in Review
Candriam SCA sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2019, closing a stake of 380,000 shares — an estimated $395K sold.
Candriam SCA first reported a position in OMED in Q4 2014 and held it in 18 quarters. The position peaked at $3.09M in Q1 2015. 0 funds tracked by Wall St. Rank hold OMED as of Q2 2019.
- Candriam SCA reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
- Candriam SCA sold 380,000 OncoMed Pharmaceuticals, Inc. shares in Q2 2019, an estimated $395K.
- Candriam SCA first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2014 and held it in 18 quarters.
- Candriam SCA's OncoMed Pharmaceuticals, Inc. position peaked at $3.09M in Q1 2015.
- 0 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2019.
Based on Candriam SCA's 13F filing for Q2 2019, filed 1 Aug 2019.